MYOTONIC DYSTROPHY TYPE 1 (DM1)
Clinical trials for MYOTONIC DYSTROPHY TYPE 1 (DM1) explained in plain language.
Never miss a new study
Get alerted when new MYOTONIC DYSTROPHY TYPE 1 (DM1) trials appear
Sign up with your email to follow new studies for MYOTONIC DYSTROPHY TYPE 1 (DM1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to control debilitating muscle disease
Disease control OngoingThis global Phase 3 trial is testing whether an intravenous drug called AOC 1001 can help control symptoms of myotonic dystrophy type 1, a genetic muscle-wasting disease. About 159 adults with a confirmed diagnosis will receive either the drug or a placebo via infusion every 8 we…
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Hope for Long-Term muscle disease control
Disease control ENROLLING_BY_INVITATIONThis study aims to learn about the long-term safety and effects of the drug VX-670 in adults with myotonic dystrophy type 1 (DM1). It is an extension study for 44 people who have already completed a previous trial with this drug. The main goal is to monitor participants for side …
Matched conditions: MYOTONIC DYSTROPHY TYPE 1 (DM1)
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC